Product Information
- 2-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-5-pyrimidinecarboxamide
BIIB-057 is a monoclonal antibody that binds to the 2-adrenergic receptor and blocks the signal transduction of the inflammatory response. BIIB-057 has been shown to inhibit the activation of primary cells from patients with bowel disease, and to have a clinical relevance in treating inflammatory bowel disease. BIIB-057 inhibits the pro-apoptotic protein, AIF, which is responsible for apoptosis in cancer cells. This drug also blocks cell signaling pathways, such as Toll-like receptor 4 (TLR4) and TLR9, found on endothelial cells and macrophages. BIIB-057 is an immunoglobulin G1 kappa humanized monoclonal antibody that targets PD-L1 and PD-L2.
Chemical properties
Technical inquiry about: 3D-VEC26196 BIIB-057
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
